Cargando…
Comparison of Prostate-Specific Promoters and the Use of PSP-Driven Virotherapy for Prostate Cancer
Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men today. Although virus-based gene therapy is a promising strategy to combat advanced prostate cancer, its current effectiveness is limited partially due to inefficient cellular transduction in...
Autores principales: | Lu, Yi, Zhang, Yu, Chang, Guimin, Zhang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581130/ https://www.ncbi.nlm.nih.gov/pubmed/23484134 http://dx.doi.org/10.1155/2013/624632 |
Ejemplares similares
-
Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter
por: Wang, Gongwei, et al.
Publicado: (2022) -
Targeting strategies of adenovirus-mediated gene therapy and virotherapy for prostate cancer
por: Cai, Zhonglin, et al.
Publicado: (2017) -
Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer
por: Nguyen, Tien V, et al.
Publicado: (2018) -
Chemopreventive Effect of PSP Through Targeting of Prostate Cancer Stem Cell-Like Population
por: Luk, Sze-Ue, et al.
Publicado: (2011) -
Correction: Chemopreventive Effect of PSP Through Targeting of Prostate Cancer Stem Cell-Like Population
por: Luk, Sze-Ue, et al.
Publicado: (2011)